Koers Vical Incorporated Nasdaq
Aandelen
US9256022032
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 6,94 mln. 6,49 mln. | Omzet 2023 | 8,01 mln. 7,49 mln. | Marktkapitalisatie | 5,25 mln. 4,91 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -21 mln. -19,64 mln. | Nettowinst (verlies) 2023 | -5 mln. -4,68 mln. | EV/omzet 2022 | -0,59 x |
Nettoliquiditeiten 2022 | 8,63 mln. 8,07 mln. | Nettoliquiditeiten 2023 | 10,87 mln. 10,16 mln. | EV/omzet 2023 | -0,7 x |
K/w-verhouding 2022 |
-0,2
x | K/w-verhouding 2023 |
-0,83
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 98,4% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 72 | 01-12-20 |
Nancy Seretta
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-16 |
Aaron Fox-Collis
AUD | Comptroller/Controller/Auditor | - | 01-07-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 72 | 01-12-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |